Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

10.7%

6 terminated/withdrawn out of 56 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

29%

16 trials in Phase 3/4

Results Transparency

55%

23 of 42 completed trials have results

Key Signals

4 recruiting23 with results

Enrollment Performance

Analytics

Phase 1
17(35.4%)
Phase 2
15(31.3%)
Phase 3
14(29.2%)
Phase 4
2(4.2%)
48Total
Phase 1(17)
Phase 2(15)
Phase 3(14)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (56)

Showing 20 of 56 trials
NCT07338214Phase 1Completed

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

Role: collaborator

NCT07126262Phase 2Recruiting

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

Role: collaborator

NCT05639933Phase 2Recruiting

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Role: collaborator

NCT05910450Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Role: collaborator

NCT07476144Phase 1Recruiting

Nordic Spirit Pouch Nicotine Pharmacokinetics Abuse Liability

Role: collaborator

NCT07463196Phase 1Recruiting

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants

Role: collaborator

NCT06476405Completed

Room Air Levels of Harmful and Potentially Harmful Constituents After Heated Tobacco Product Use and Cigarettes

Role: collaborator

NCT06017609Phase 2Active Not Recruiting

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

Role: collaborator

NCT02065336Phase 2Terminated

A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Role: collaborator

NCT05388474Active Not Recruiting

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Role: collaborator

NCT04090957Phase 3Completed

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

Role: collaborator

NCT05914805Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

Role: collaborator

NCT06015841Phase 2Active Not Recruiting

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

Role: collaborator

NCT06956495Phase 2Completed

Efficacy and Tolerability of Tasipimidine in Sleepless Patients

Role: collaborator

NCT03744910Phase 3Terminated

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Role: collaborator

NCT00981058Phase 3Completed

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Role: collaborator

NCT03444324Phase 3Completed

Adjusted Fibrinogen Replacement Strategy

Role: collaborator

NCT04761198Phase 1Completed

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

Role: collaborator

NCT02727699Phase 2Completed

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Role: collaborator

NCT04209543Phase 3Completed

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Role: collaborator